Cargando…
A real‐world study of glucocorticoid treatment in COVID‐19 patients with different disease severities
Autores principales: | Jiao, Xiaofei, Wang, Ya, Liu, Dan, Zeng, Shaoqing, Chi, Jianhua, Li, Ruyuan, Yu, Yang, Yu, Ruidi, Wang, Siyuan, Yuan, Yuan, Gao, Yue, Xu, Sen, Li, Chunrui, Gao, Qinglei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724098/ https://www.ncbi.nlm.nih.gov/pubmed/33377641 http://dx.doi.org/10.1002/ctm2.235 |
Ejemplares similares
-
Immunity‐modulated sex disparity on COVID‐19 prognosis
por: Liu, Dan, et al.
Publicado: (2020) -
Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort study
por: Liu, Dan, et al.
Publicado: (2020) -
Development and validation of an online model to predict critical COVID-19 with immune-inflammatory parameters
por: Gao, Yue, et al.
Publicado: (2021) -
Glucocorticoid benefits the ventilatory function of severe/critical COVID-19 patients
por: Xiong, Xiaoming, et al.
Publicado: (2021) -
Alteration of serum markers in COVID‐19 and implications on mortality
por: Liu, Dan, et al.
Publicado: (2020)